These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
2940 related items for PubMed ID: 20107292
1. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men. Siris ES, Baim S, Nattiv A. Postgrad Med; 2010 Jan; 122(1):82-90. PubMed ID: 20107292 [Abstract] [Full Text] [Related]
2. [Usefulness of FRAX and future issues in women's health]. Hashimoto K, Ishitani K, Ohta H. Clin Calcium; 2009 Dec; 19(12):1742-8. PubMed ID: 19949265 [Abstract] [Full Text] [Related]
5. Frequency of FRAX risk factors in osteopenic postmenopausal women with and without history of fragility fracture. Baró F, Cano A, Sánchez Borrego R, Ferrer J, González Rodríguez SP, Neyro JL, Rodriguez Bueno E, Sancho C, Inaraja V, Fernández C, Corral C, FROSPE Study Group. Menopause; 2012 Nov; 19(11):1193-9. PubMed ID: 22948137 [Abstract] [Full Text] [Related]
6. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA). Siris ES, Brenneman SK, Miller PD, Barrett-Connor E, Chen YT, Sherwood LM, Abbott TA. J Bone Miner Res; 2004 Aug; 19(8):1215-20. PubMed ID: 15231007 [Abstract] [Full Text] [Related]
7. Identification of osteopenic women at high risk of fracture: the OFELY study. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. J Bone Miner Res; 2005 Oct; 20(10):1813-9. PubMed ID: 16160738 [Abstract] [Full Text] [Related]
9. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML. Arch Intern Med; 2004 May 24; 164(10):1108-12. PubMed ID: 15159268 [Abstract] [Full Text] [Related]
10. Low bone mineral density and fracture burden in postmenopausal women. Cranney A, Jamal SA, Tsang JF, Josse RG, Leslie WD. CMAJ; 2007 Sep 11; 177(6):575-80. PubMed ID: 17846439 [Abstract] [Full Text] [Related]
12. FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Ström O, Borgström F, Kleman M, McCloskey E, Odén A, Johansson H, Kanis JA. Bone; 2010 Aug 11; 47(2):430-7. PubMed ID: 20493983 [Abstract] [Full Text] [Related]
13. Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies. Boonen S, Klemes AB, Zhou X, Lindsay R. J Am Geriatr Soc; 2010 Apr 11; 58(4):658-63. PubMed ID: 20345865 [Abstract] [Full Text] [Related]
14. Osteoporosis in older men and women. Kenny AM, Joseph C, Taxel P, Prestwood KM. Conn Med; 2003 Sep 11; 67(8):481-6. PubMed ID: 14587128 [Abstract] [Full Text] [Related]
18. Low bone mass--assessing absolute fracture risk and the need to treat younger postmenopausal women. Honig S. Bull NYU Hosp Jt Dis; 2009 Sep 11; 67(3):281-4. PubMed ID: 19852751 [Abstract] [Full Text] [Related]